Kristen Stewart: Okay. That’s helpful. Thanks very much.
Operator: Thank you. One moment for our next question. And our next question comes from the line of Vik Chopra from Wells Fargo. Your question, please.
Vik Chopra: Hey, good afternoon, and thanks for taking the question. So, thanks for providing all the color on the guidance, I’m just wondering if you could share what’s assumed in your guidance for the rest of the higher-growth businesses. And then, I have a follow-up, please.
Todd Garner: Yeah, no change. Vik, we continue to expect all of our high-growth businesses to perform as they have been. So again, just to make everybody feel comfortable that’s over 20% for AirSeal and Buffalo. Twice the market for Foot and Ankle side of the business, and obviously Biorez is a geometric type of growth engine. So, no change to how we view those growth drivers.
Curt Hartman: Yeah. I would just adding on to that point to the conference at the beginning year where we put up slides that talked about the percentage of portfolio that was growing double-digit, growing single-digits or declining. And if you just look at that mix, it’s a pretty healthy portfolio. So that in and of itself underlies history of the business and our portfolio was only getting stronger with new product introductions. So, I feel really good about our portfolio, not only the ones we’ve identified as high growth, but the rest of the portfolio and our outlook.
Vik Chopra: Got it. Thanks. And then just a follow-up I had on BioBrace, maybe just talk about your view on how quickly the product can grow in 2024. And any thoughts you can share with respect to your approach to the market and competitive strategy? Thank you.
Todd Garner: Well, I mean it’s still early days for BioBrace in the marketplace and for CONMED. And we had said, this year it would be high-single-digits and we exceeded that, and we feel very good. And part of my script was talking about sales channel expansion. And that means, geographic expansion as registrations and approvals come through, which we’ve been working on since day one. But it also means leveraging our Foot and Ankle sales force. We have a sales force that we didn’t have really until right before we acquired BioBrace, and there is a clinical need in Foot and Ankle for a product like BioBrace. And that sales team is being ramped up, educated, trained and we feel very optimistic that that is a great channel for that product as well.
So there’s a lot of growth drivers here in our core Sports Medicine channel for knee and shoulder and candidly other applications come by the booth on Wednesday at Academy. And you’ll see a lot of surgeon presentations related to BioBrace. Our outlook, and this is really exciting, because it’s clinically differentiated. It is second-generation technology, it is game-changing for patients and clinicians, and I’ve said many times, it’s the single most contacted product that I have surgeons reaching out to me expressing their pleasure with the product and how it’s changed patient outcomes. So, we’re very optimistic about BioBrace.
Operator: Thank you. One moment for our next question. And our next question comes from the line of Mike Matson from Needham & Company. Your question, please.
Mike Matson: Yeah, thanks. So, just in the Orthopedics business, I guess, I want to better understand what’s happening or what happened with the tissue situation. So, obviously, there’s some kind of direct impact there from the shortage and maybe, I don’t know if you’ve disclosed before how big a part of the Orthopedics sales come directly from sales of that. But then I was also wondering if there — was there some kind of spillover effect where, by not having those products that you maybe lose procedures or lose other products that would have gotten sold for those cases.
Curt Hartman: Yeah, Mike, I think — and I go back to what we said last quarter, but also what I think Todd had in his commentary, the supply disruption in the MTF portfolio is a smaller part of our business, had a bigger impact on margins because of the margin profile. What we highlighted in Q3 and what got better, but not as much as we had hoped was just a general supplier challenge that was impacting a larger portion of our Sports Medicine and our Foot and Ankle business. Foot and Ankle, a little bit different, because that’s more supplier integration whereas the standard Sports Medicine business was more just supplier delays and disruptions that candidly caught up to us. We thought we had been doing a pretty good job. But as things were moving forward, we had some disruptions.
And as you know in that business, if you don’t have the product for the case, you can try to substitute, or they find an alternative from a competitor. So, we just miss cases, and that was the bigger impact in the quarter. That is improving as we exited the year. It’s improving in the first quarter, and we’ll be back fully on offense as we get to Q2 broadly speaking in Orthopedics. So, I wouldn’t get hung-up on the MTF portion of that that as Todd said was more about the margin hit. The revenue hit was more on the general Sports Medicine side because of lost cases, because of supply disruption.
Mike Matson: Okay. Got it. Sorry, I guess, when I heard supply issues, I was confusing that with the MTF thing, but okay. And then just you’re sure that there’s no other competitive issues in that business. I mean Stryker is launching a new camera and power tools, and they seemed to be doing really well. I mean, I know that’s capital but — or any other product launches from competitors that are hurting you?
